Literature DB >> 9683602

A defect in the regional deposition of adipose tissue (partial lipodystrophy) is encoded by a gene at chromosome 1q.

S N Jackson1, J Pinkney, A Bargiotta, C D Veal, T A Howlett, P G McNally, R Corral, A Johnson, R C Trembath.   

Abstract

Partial lipodystrophy (PLD), also known as "Dunnigan-Kobberling syndrome," is transmitted as a highly penetrant autosomal dominant disorder that is characterized by a dramatic absence of adipose tissue in the limbs and trunk, more evident in females than in males. In contrast, fat is retained on the face, in retro-orbital space, and at periserous sites. Associated metabolic abnormalities, including insulin resistance, hyperinsulinemia, and dyslipidemia, are referred to as "metabolic syndrome X" (Reaven 1988). Despite the intense interest in the genetic determinants underlying fat deposition, the genes involved in the lipodystrophic syndromes have not been identified. We ascertained two multigeneration families, with a combined total of 18 individuals with PLD, and performed a genomewide search. We obtained conclusive evidence for linkage of the PLD locus to microsatellite markers on chromosome 1q21 (D1S498, maximum LOD score 6.89 at recombination fraction .00), with no evidence of heterogeneity. Haplotype and multipoint analysis support the location of the PLD locus within a 21.2-cM chromosomal region that is flanked by the markers D1S2881 and D1S484. These data represent an important step in the effort to isolate and characterize the PLD gene. The identification of the gene will have important implications for the understanding of both developmental and metabolic aspects of the adipocyte and may prove useful as a single-gene model for the common metabolic disorder known as "syndrome X."

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9683602      PMCID: PMC1377312          DOI: 10.1086/301971

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  22 in total

1.  Metabolic studies in familial partial lipodystrophy of the lower trunk and extremities.

Authors:  M B Davidson; R T Young
Journal:  Diabetologia       Date:  1975-12       Impact factor: 10.122

2.  Familial lipoatrophic diabetes with dominant transmission. A new syndrome.

Authors:  M G Dunnigan; M A Cochrane; A Kelly; J W Scott
Journal:  Q J Med       Date:  1974-01

3.  Faster sequential genetic linkage computations.

Authors:  R W Cottingham; R M Idury; A A Schäffer
Journal:  Am J Hum Genet       Date:  1993-07       Impact factor: 11.025

Review 4.  Banting lecture 1988. Role of insulin resistance in human disease.

Authors:  G M Reaven
Journal:  Diabetes       Date:  1988-12       Impact factor: 9.461

5.  Localization of the gene for familial partial lipodystrophy (Dunnigan variety) to chromosome 1q21-22.

Authors:  J M Peters; R Barnes; L Bennett; W M Gitomer; A M Bowcock; A Garg
Journal:  Nat Genet       Date:  1998-03       Impact factor: 38.330

6.  Obesity genes: beneficial effects in heterozygous mice.

Authors:  D L Coleman
Journal:  Science       Date:  1979-02-16       Impact factor: 47.728

7.  Strategies for multilocus linkage analysis in humans.

Authors:  G M Lathrop; J M Lalouel; C Julier; J Ott
Journal:  Proc Natl Acad Sci U S A       Date:  1984-06       Impact factor: 11.205

8.  Partial lipoatrophy with insulin resistant diabetes and hyperlipidaemia (Dunnigan syndrome).

Authors:  J Burn; M Baraitser
Journal:  J Med Genet       Date:  1986-04       Impact factor: 6.318

9.  Assignment of the human CRABP-II gene to chromosome 1q21 by nonisotopic in situ hybridization.

Authors:  J T Elder; A Aström; U Pettersson; J J Voorhees; J M Trent
Journal:  Hum Genet       Date:  1992-07       Impact factor: 4.132

10.  Familial partial lipodystrophy: two types of an X linked dominant syndrome, lethal in the hemizygous state.

Authors:  J Köbberling; M G Dunnigan
Journal:  J Med Genet       Date:  1986-04       Impact factor: 6.318

View more
  8 in total

1.  Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice.

Authors:  O Gavrilova; B Marcus-Samuels; D Graham; J K Kim; G I Shulman; A L Castle; C Vinson; M Eckhaus; M L Reitman
Journal:  J Clin Invest       Date:  2000-02       Impact factor: 14.808

2.  Genomic anatomy of a premier major histocompatibility complex paralogous region on chromosome 1q21-q22.

Authors:  T Shiina; A Ando; Y Suto; F Kasai; A Shigenari; N Takishima; E Kikkawa; K Iwata; Y Kuwano; Y Kitamura; Y Matsuzawa; K Sano; M Nogami; H Kawata; S Li; Y Fukuzumi; M Yamazaki; H Tashiro; G Tamiya; A Kohda; K Okumura; T Ikemura; E Soeda; N Mizuki; M Kimura; S Bahram; H Inoko
Journal:  Genome Res       Date:  2001-05       Impact factor: 9.043

Review 3.  Lipoatrophic diabetes and other related syndromes.

Authors:  Elif Arioglu Oral
Journal:  Rev Endocr Metab Disord       Date:  2003-03       Impact factor: 6.514

4.  Anatomical histological and mesoscopic study of the adipose tissue of the orbit.

Authors:  D Bremond-Gignac; H Copin; O Cussenot; J-P Lassau; D Henin
Journal:  Surg Radiol Anat       Date:  2004-05-04       Impact factor: 1.246

5.  Adipokines and the insulin resistance syndrome in familial partial lipodystrophy caused by a mutation in lamin A/C.

Authors:  S P Y Wong; M Huda; P English; A Bargiota; J P H Wilding; A Johnson; R Corrall; J H Pinkney
Journal:  Diabetologia       Date:  2005-11-17       Impact factor: 10.122

Review 6.  Diseases of the nuclear envelope.

Authors:  Howard J Worman; Cecilia Ostlund; Yuexia Wang
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-02       Impact factor: 10.005

7.  Mutational and haplotype analyses of families with familial partial lipodystrophy (Dunnigan variety) reveal recurrent missense mutations in the globular C-terminal domain of lamin A/C.

Authors:  R A Speckman; A Garg; F Du; L Bennett; R Veile; E Arioglu; S I Taylor; M Lovett; A M Bowcock
Journal:  Am J Hum Genet       Date:  2000-04       Impact factor: 11.025

Review 8.  Insulin resistance in human partial lipodystrophy.

Authors:  R A Hegele
Journal:  Curr Atheroscler Rep       Date:  2000-09       Impact factor: 5.113

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.